A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
About this trial
This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease focused on measuring chronic obstructive pulmonary disease, COPD
Eligibility Criteria
Inclusion Criteria: Completion of the 52-week treatment period in either parent GB43311 or GB44332 Exclusion Criteria: Withdrawal of consent and/or premature discontinuation from parent study Any permanent discontinuation of study drug in parent study Significant non-compliance in the parent study, specifically defined as missing scheduled visits, per investigator's judgment Any new diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines since enrolling in the parent study Any new clinically significant pulmonary disease other than COPD (e.g., pulmonary fibrosis, sarcoidosis, chronic pulmonary embolism or primary pulmonary hypertension, alpha-1-antitrypsin deficiency) since enrolling in the parent study Any new unstable cardiac disease, myocardial infarction, or New York Heart Association Class III or IV heart failure since enrolling in the parent study
Sites / Locations
- SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDSRecruiting
- Jasper Summit Research LLCRecruiting
- Pulmonary Associates of Mobile PCRecruiting
- Cadena Care Institute, LLCRecruiting
- St Francis Medical Institute ClinEdge PPDSRecruiting
- Flourish Research - Leesburg - PPDSRecruiting
- Pulmonary Specialists of the Palm BeachesRecruiting
- Florida Institute for Clinical Research, LLCRecruiting
- Revive Research InstituteRecruiting
- Oakland Medical ResearchRecruiting
- Midwest Chest ConsultantsRecruiting
- Midwest Clinical Research LLCRecruiting
- Sierra Clinical Research - ClinEdge - PPDSRecruiting
- Clinical Research of GastoniaRecruiting
- Carolina Research CenterRecruiting
- Southeastern Research CenterRecruiting
- South Texas Medical Research Institute, Inc., dba TTS Research ? ClinEdge ? PPDSRecruiting
- Sherman Clinical Research - ClinEdge - PPDSRecruiting
- TrialsWest Pty LtdRecruiting
Arms of the Study
Arm 1
Experimental
Open-Label Extension
Eligible participants from parent studies GB43311 and GB44332 will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W) until the end of the study